Cytotoxic to a panel of cancer cell lines (breast, gastric, lymphoma, melanoma); delayed xenograft tumor growth and disease progression partly via p53 activation and death receptor-5 (DR-5) upregulation. Here, TP53 is linked to lymphoma.